1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Epilepsy Drugs Market in Europe - Market Analysis 2015-2019

Epilepsy Drugs Market in Europe - Market Analysis 2015-2019

  • September 2015
  • -
  • Infiniti Research Limited
  • -
  • 64 pages

Summary

Table of Contents

Search Inside

About epilepsy
Epilepsy refers to a spectrum of brain disorders manifested by benign to severe, disabling, and life-threatening symptoms. It is caused by factors ranging from brain malformations and tumors to meningitis, high-risk pregnancies, and trauma during birth. When the underlying cause of the disease is unidentified, as is witnessed in the majority of cases, it is known as idiopathic epilepsy. An imbalance between the inhibitory and excitatory signals of the brain, leading to a sudden onset of excitation, results in seizures.

Technavio's analysts forecast the epilepsy drugs market in Europe to grow at a CAGR of 3.22% over the period 2014-2019.

Covered in this report
The report includes the present scenario and the growth prospects of the epilepsy drugs market in Europe for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of epilepsy.

Technavio's report, Epilepsy Drugs Market in Europe 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as market segmentation and pipeline landscape. The report includes a discussion of the key vendors operating in this market.

Key Vendors
- Eisai
- GlaxoSmithKline
- Pfizer
- UCB

Other prominent vendors
- AbbVie
- Janssen Pharmaceuticals
- Lundbeck
- Meda
- Novartis
- Roche
- Shire
- Sunovion Pharmaceuticals
- Supernus Pharmaceuticals
- Upsher-Smith
- Valeant Pharmaceuticals

Market driver
- Unmet medical needs
- For a full, detailed list, view our report

Market challenge
- Patent expiry
- For a full, detailed list, view our report

Market trend
- Reformulation of marketed drugs
- For a full, detailed list, view our report


Key Questions Answered in this Report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaFocus: Tauopathies - Global Market Analysis

PharmaFocus: Tauopathies - Global Market Analysis

  • $ 9495
  • Industry report
  • February 2017
  • by GlobalData

PharmaFocus: Tauopathies - Global Market Analysis Summary Tauopathies are a class of more than 20 neurodegenerative diseases characterized by tau protein aggregation in the brain. There are currently no ...

Epiomic Epidemiology Series: Bell’s Palsy Forecast in 15 Major Markets 2017-2027

Epiomic Epidemiology Series: Bell’s Palsy Forecast in 15 Major Markets 2017-2027

  • $ 5112
  • Industry report
  • February 2017
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Bell’s palsy in 15 Major Markets Bell's palsy, also known as idiopathic facial nerve palsy, is a weakness of the muscles on one side ...

Epiomic Epidemiology Series: Muscular Dystrophies Forecast in 12 Major Markets 2017-2027

Epiomic Epidemiology Series: Muscular Dystrophies Forecast in 12 Major Markets 2017-2027

  • $ 5112
  • Industry report
  • January 2017
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Muscular Dystrophies in 12 Major Markets The muscular dystrophies (MD) are a group of more than 30 genetic diseases characterized by ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.